Clinical trial · Observational
Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study
NCT05817149CI-TRIAL-00065745completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We want to test if an association between sentinel lymph node biopsy (SLBN) and a systemic inflammatory response can be made.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with melanoma
- description
- Patients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.
- interventionNames
- Procedure: Blood samples
Primary outcomes (1)
- measure
- Neutrophil-to-lymphocyte ratio
- timeFrame
- 1 Day
- description
- Ratio between neutrophil granulocytes and lymphocytes
Secondary outcomes (2)
- measure
- Pro-inflammatory cytokines
- timeFrame
- 1 Day
- description
- IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α, and IFN-γ
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (\>18 years of age) * Diagnosed with invasive cutaneous melanoma * Eligible for SLNB (Melanoma stage ≥ T1b) * Obtained signed informed consent Exclusion Criteria: * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.